https://www.ayvakithcp.com/component---src-pages-advsm-about-ayvakit-overview-js-4016485f11e7e275b4ed.js

1"use strict";(self.webpackChunkgatsby_starter_default=self.webpackChunkgatsby_starter_default||[]).push([[6632],{251:function(e,M){M.A="data:image/svg+xml;base64,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"},3439:function(e,M,t){var N=t(6540),a=(t(4810),t(6614));M.A=({className:e,heading:M,copy:t,type:i,btncopy:I,url:c,site:D="gist",buttontheme:n="",ctatheme:l="",btntexttransform:j="none",icon:g,iconcopy:u,alt:s,stripes:A=!1})=>N.createElement(N.Fragment,null,N.createElement("div",{className:`row cta-advanced ${D} ${l} ${e}`},N.createElement("div",{className:"inner-shell"},N.createElement("div",{className:"column"},g&&N.createElement("div",{className:"icon mb-1 md_mb-0"},N.createElement("img",{src:g,alt:s})),u&&N.createElement("div",{className:"icon copy mb-1 md_mb-0"},N.createElement("p",{className:"cta-header"},u)),N.createElement("div",{className:"center main-content"},M&&N.createElement("h5",{dangerouslySetInnerHTML:{__html:M}}),N.createElement("p",{className:"cta-header",dangerouslySetInnerHTML:{__html:t}})),n&&N.createElement("div",{className:"center md_mt-1 lg_mt-1 btnsection"},N.createElement(a.A,{copy:I,url:c,site:D,buttontheme:n,texttransform:j}))))))},8844:function(e,M,t){var N=t(6540),a=t(6614);

1M.A=({heading:e,copy:M,url:t,site:i="advsm",buttontheme:I="dark-blue-yellow",texttransform:c="uppercase",target:D,type:n,className:l=""})=>N.createElement("section",{className:`page-bottom-cta ${l}`},N.createElement("div",{className:"inner-container"},N.createElement("h3",{dangerouslySetInnerHTML:{__html:e}}),N.createElement(a.A,{copy:M,url:t,site:i,buttontheme:I,texttransform:c,target:D,type:n})))},8966:function(e,M,t){M.A=t.p+"static/icon-ayvakit-overview-advsm-6bb54d9735477b972bb6a382f900d19b.svg"},9106:function(e,M,t){t.r(M),t.d(M,{Head:function(){return u},default:function(){return s}});var N=t(6540),a=t(4607),i=t(5121),I=t(8154),c=t(6614),D=t(8844),n=t(1215),l=t(3439),j=t(251),g=t.p+"static/icon-moa-0c76476f36dc8655bd3287f1467d6d26.png";t(8966);const u=()=>N.createElement(i.A,{title:"AYVAKIT® (avapritinib) Indication | Advanced SM Treatment",description:"Assess how AYVAKIT®, the only FDA-approved treatment for both AdvSM and ISM, targets the KIT D816V mutation. See ISI and PI for more info."});var s=()=>N.createElement(a.A,{site:"advsm",advsmBreadcrumb:"about-ayvakit",isiType:"advsm-ism"},N.createElement("div",{id:"advsm-container",className:"advsm-about-ayvakit-overview"},N.createElement(n.A,{type:"advsm",headline:N.createElement(N.Fragment,null,"The ONLY treatment FDA-approved for both Advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM)",N.createElement("sup",null,"1")),topbullets:N.createElement(N.Fragment,null,N.createElement("li",null,N.createElement("u",null,"Limitations of Use"),": AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 10",N.createElement("sup",null,"9"),"/L."),N.createElement("li",null,N.createElement("u",null,"Limitations of Use"),": AYVAKIT is not recommended for patients with ISM with platelet counts of <50 x 10",N.createElement("sup",null,"9"),"/L.")),hidesidebar:!0}),N.createElement("div",{className:"inner-container"},N.createElement("div",{className:"container-padding"},N.createElement("div",{className:"row main-content"},N.createElement("div",{className:"advsm-overview-content"},N.createElement("p",{className:"advsm-overview-copy"},"AYVAKIT targets the KIT D816V mutation, the underlying driver in ~95% of SM cases, and is the only FDA-approved treatment for both ISM and AdvSM with up to ~4 years of clinical study follow-up data. Explore efficacy, safety, and dosing information across the spectrum of both AdvSM and ISM.",N.createElement("sup",null,"1-5")),N.createElement("section",{className:"advsm-overview-main-section"},N.createElement("div",{className:"row advsm-map-row"},N.createElement("div",{className:"column small-12 medium-4 col-outer col-left img-p-0 "},N.createElement(l.A,{heading:"Targets the driver of&nbsp;disease<sup>1,6</sup>",copy:"<p class='light-blue-bullets'>AYVAKIT inhibits KIT D816V, the underlying driver causing the overproduction of abnormal mast cells in both AdvSM and ISM*</p> <p class='ref'><span class='hang hang-sm'>*</span>AYVAKIT demonstrated greater inhibitory potency for KIT D816V vs wild type KIT in cellular assays.</p>",ctatheme:"inside-icon-w-bullets",className:"no-header-padding",icon:g})),N.createElement("div",{className:"column small-12 medium-4 col-outer img-p-0"},N.createElement(l.A,{heading:"Clinical benefit in both AdvSM and ISM<sup>1,2,7,8</sup>",copy:"<p class='light-blue-bullets'>Efficacy and safety established in EXPLORER + PATHFINDER (AdvSM) and PIONEER (ISM) clinical trials</p> <p class='light-blue-bullets'>Long-term follow-up data is available through 4 years in AdvSM and ~3.5 years in ISM</p>",ctatheme:"inside-icon-w-bullets",className:"no-header-padding",icon:j.A})),N.createElement("div",{className:"column small-12 medium-4 col-outer img-p-0"},N.createElement(l.A,{heading:"Generally well&#8209;characterized safety profile<sup>1,2,7</sup>",copy:"<p class='light-blue-bullets'>~4 years of follow-up safety data in AdvSM and ISM</p>",ctatheme:"inside-icon-w-bullets",className:"no-header-padding",icon:"data:image/svg+xml;base64,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"}))),N.createElement("div",{className:"row advsm-map-row multi-cta-container"},N.createElement("div",{className:"container-heading"},N.createElement("p",null,"Learn more about AYVAKIT clinical data")),N.createElement("div",{className:"flex-row-container"},N.createElement("div",{className:"flex-child1"},N.createElement("p",{className:"child-heading"},"AdvSM"),N.createElement("div",{className:"button-group"},N.createElement(c.A,{copy:"VIEW EFFICACY",url:"/advsm/efficacy/",buttontheme:"sky-blue-white-yellow-small-font",texttransform:"uppercase"}),N.createElement(c.A,{copy:"VIEW SAFETY",url:"/advsm/safety-data/",buttontheme:"sky-blue-white-navy-small-font",texttransform:"uppercase"}))),N.createElement("div",{className:"flex-child2"},N.createElement("p",{className:"child-heading"},"ISM"),N.createElement("div",{className:"button-group"},N.createElement(c.A,{copy:"VIEW EFFICACY",url:"/ism/efficacy/",buttontheme:"sky-blue-white-yellow-small-font",texttransform:"uppercase"}),N.createElement(c.A,{copy:"VIEW SAFETY",url:"/ism/safety/",buttontheme:"sky-blue-white-navy-small-font",texttransform:"uppercase",className:"ism-safety-btn"})))))))))),N.createElement(D.A,{heading:"Learn about the selective targeting mechanism of AYVAKIT",copy:"Explore the mechanism of action",url:"/advsm/about-ayvakit/moa/",site:"advsm",buttontheme:"dark-blue-yellow"}),N.createElement("div",{className:"inner-container"},N.createElement("section",{className:"advsm-about-references"},N.createElement("p",{className:"references"},N.createElement("b",null,"References: 1.")," AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024."," ",N.createElement("b",null,"2.")," Gotlib J et al. ",N.createElement("i",null,"Blood Adv"),". 2026;10(10):3676-3689."," ",N.createElement("b",null,"3.")," Kristensen T et al. ",N.createElement("i",null,"Am J Hematol"),". 2014;89(5):493-498."," ",N.createElement("b",null,"4.")," Garcia-Montero AC et al. ",N.createElement("i",null,"Blood"),". 2006;108(7):2366-2372."," ",N.createElement("b",null,"5.")," Ungerstedt J et al. ",N.createElement("i",null,"Cancers (Basel)"),". 2022;14(16):3942."," ",N.createElement("b",null,"6.")," Gülen T et al. ",N.createElement("i",null,"J Intern Med"),". 2016;279(3):211-228."," ",N.createElement("b",null,"7.")," Data on file. Blueprint Medicines Corporation, Cambridge, MA."," ",N.createElement("b",null,"8.")," Gotlib J et al. ",N.createElement("i",null,"NEJM Evid"),". 2023;2(6):EVIDoa2200339."," ")))),N.createElement(I.A,null,N.createElement("script",{type:"application/ld+json"},'\n          {\n            "@context": "https://schema.org",\n            "@type": "MedicalWebPage",\n            "headline": "Overview of AYVAKIT in AdvSM | AYVAKIT® (avapritinib)",\n            "url": "https://www.ayvakithcp.com/advsm/about-ayvakit/overview/",\n            "description": "An overview of AYVAKIT (avapritinib) for Advanced Systemic Mastocytosis. See ISI and PI for more info.",\n            "about": {\n              "@type": "MedicalCondition",\n              "name": "Advanced Systemic Mastocytosis",\n              "alternateName": "AdvSM"\n            }\n          }\n        ')))}}]);
2//# sourceMappingURL=component---src-pages-advsm-about-ayvakit-overview-js-4016485f11e7e275b4ed.js.map